Integrated Report

Overview

The report covers Sumitomo Dainippon Pharma's performance and strategy for fiscal 2019 (ended March 31, 2020). Highlights include the company's major strategic alliance with Roivant Sciences, acquiring several late-stage pipeline assets such as relugolix and vibegron alongside data and digital technology platforms. Consolidated revenue reached 482.8 billion yen, driven by strong growth in key pharmaceutical products in Japan, North America, and China. In sustainability, the company established updated 2030 environmental targets, including a 35% reduction in Scope 1 and 2 GHG emissions compared to fiscal 2017 levels.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2019-2020
Period: 1 April 2019 – 31 March 2020
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services